Published in J Biol Chem on March 26, 2008
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
Inhibition of p66ShcA longevity gene rescues podocytes from HIV-1-induced oxidative stress and apoptosis. J Biol Chem (2009) 1.24
Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest (2011) 1.13
Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet (2013) 1.02
Gene regulation by non-coding RNAs. Crit Rev Biochem Mol Biol (2013) 0.92
Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models. Neurosci Lett (2010) 0.83
A high-throughput screen to identify inhibitors of SOD1 transcription. Front Biosci (Elite Ed) (2012) 0.80
Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS. Antioxid Redox Signal (2009) 0.79
Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol (2016) 0.78
Identification of human monoclonal antibodies specific for human SOD1 recognizing distinct epitopes and forms of SOD1. PLoS One (2013) 0.78
Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain. Mol Ther Nucleic Acids (2016) 0.77
Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts. Eur J Hum Genet (2014) 0.77
Non-Viral Nucleic Acid Delivery Strategies to the Central Nervous System. Front Mol Neurosci (2016) 0.75
Structural Dynamics of Human Argonaute2 and Its Interaction with siRNAs Designed to Target Mutant tdp43. Adv Bioinformatics (2016) 0.75
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (1994) 18.08
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci U S A (2001) 7.12
Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 6.35
Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol (2007) 6.11
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
Revealing the world of RNA interference. Nature (2004) 5.92
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21
siRNA function in RNAi: a chemical modification analysis. RNA (2003) 4.93
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 4.72
RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol (2006) 4.38
RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell (2002) 3.81
Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A (2003) 3.74
CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene (2005) 3.17
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A (2007) 3.07
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res (2003) 2.64
Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain (2005) 2.64
Noise amidst the silence: off-target effects of siRNAs? Trends Genet (2004) 2.38
Efficacy of tribromoethanol anesthesia in mice. Lab Anim Sci (1993) 2.00
siRNA relieves chronic neuropathic pain. Nucleic Acids Res (2004) 1.96
Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun (2002) 1.75
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (2007) 1.66
Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med (1994) 1.58
Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett (2004) 1.57
Isolation and solubilization of proteins after TRIzol extraction of RNA and DNA from patient material following prolonged storage. Biotechniques (2007) 1.36
Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis (2006) 1.30
Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev (2003) 1.28
Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem Biol (2007) 1.16
Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J Biol Chem (2003) 1.11
On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest (2007) 1.05
Synthesis of uridine phosphoramidite analogs: reagents for site-specific incorporation of photoreactive sites into RNA sequences. Bioconjug Chem (1995) 1.01
Chronic lumbar catheterization of the spinal subarachnoid space in mice. J Neurosci Methods (2004) 1.00
Technology insight: therapeutic RNA interference--how far from the neurology clinic? Nat Clin Pract Neurol (2007) 0.99
Expression of interferon-induced genes in different tissues of mice. J Virol (1988) 0.92
Mechanism and treatment of motoneuron degeneration in ALS: what have SOD1 mutants told us? Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 0.87
RNAi therapy for neurodegenerative diseases. Curr Top Dev Biol (2006) 0.84
Instrumentation for neuromodulation. Arch Med Res (2000) 0.76
Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 22.18
Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54. PLoS Biol (2006) 6.41
siRNA function in RNAi: a chemical modification analysis. RNA (2003) 4.93
RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell (2002) 3.81
Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet (2006) 3.23
Specific and potent RNAi in the nucleus of human cells. Nat Struct Mol Biol (2005) 3.16
Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell (2009) 3.05
Small RNA-mediated regulation of iPS cell generation. EMBO J (2011) 2.95
Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol (2008) 2.83
RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol Cell (2007) 2.72
Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog (2006) 2.61
Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion (2005) 2.24
Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proc Natl Acad Sci U S A (2006) 2.10
Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol (2004) 2.05
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell (2003) 1.88
Small RNAs: regulators and guardians of the genome. J Cell Physiol (2007) 1.86
An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res (2005) 1.83
Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol (2005) 1.78
The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL. Proc Natl Acad Sci U S A (2013) 1.78
Reactive astrocytes secrete lcn2 to promote neuron death. Proc Natl Acad Sci U S A (2013) 1.59
FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet (2011) 1.57
Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci (2002) 1.55
Pol II-expressed shRNA knocks down Sod2 gene expression and causes phenotypes of the gene knockout in mice. PLoS Genet (2006) 1.49
ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci (2003) 1.46
The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure. Proc Natl Acad Sci U S A (2002) 1.46
TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc Natl Acad Sci U S A (2002) 1.44
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc (2008) 1.43
Tat stimulates cotranscriptional capping of HIV mRNA. Mol Cell (2002) 1.43
Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J Biol Chem (2004) 1.42
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol (2010) 1.39
MicroRNAs encoded by Kaposi's sarcoma-associated herpesvirus regulate viral life cycle. EMBO Rep (2010) 1.34
The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. PLoS One (2010) 1.32
Aberrantly increased hydrophobicity shared by mutants of Cu,Zn-superoxide dismutase in familial amyotrophic lateral sclerosis. J Biol Chem (2005) 1.30
Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis (2006) 1.30
Potent RNAi by short RNA triggers. RNA (2008) 1.29
Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J Neurochem (2002) 1.27
Deep annotation of mouse iso-miR and iso-moR variation. Nucleic Acids Res (2012) 1.27
Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol (2004) 1.26
An enhanced U6 promoter for synthesis of short hairpin RNA. Nucleic Acids Res (2003) 1.24
Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation. Biochemistry (2002) 1.21
Multiple shRNAs expressed by an inducible pol II promoter can knock down the expression of multiple target genes. Biotechniques (2006) 1.21
Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci (2007) 1.20
microRNAs modulate iPS cell generation. RNA (2011) 1.19
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res (2005) 1.19
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. J Med Chem (2006) 1.17
Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem Biol (2007) 1.16
A kinase inhibitor screen identifies small-molecule enhancers of reprogramming and iPS cell generation. Nat Commun (2012) 1.14
Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest (2011) 1.13
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des (2007) 1.12
Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J Biol Chem (2003) 1.11
S-nitrosothiol depletion in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2006) 1.11
Pathogenic mutation in VPS35 impairs its protection against MPP(+) cytotoxicity. Int J Biol Sci (2013) 1.09
A construct with fluorescent indicators for conditional expression of miRNA. BMC Biotechnol (2008) 1.08
Discovery of nonsteroidal anti-inflammatory drug and anticancer drug enhancing reprogramming and induced pluripotent stem cell generation. Stem Cells (2011) 1.08
Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2014) 1.08
Dissecting RNA-interference pathway with small molecules. Chem Biol (2005) 1.07
A quantitative histochemical assay for activities of mitochondrial electron transport chain complexes in mouse spinal cord sections. J Neurosci Methods (2002) 1.06
Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J (2013) 1.05
Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. Retrovirology (2004) 1.05
LIM-domain proteins, LIMD1, Ajuba, and WTIP are required for microRNA-mediated gene silencing. Proc Natl Acad Sci U S A (2010) 1.03
Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet (2013) 1.02
Entorhinal cortical neurons are the primary targets of FUS mislocalization and ubiquitin aggregation in FUS transgenic rats. Hum Mol Genet (2012) 1.02
Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res (2011) 1.02
Sustained expression of TDP-43 and FUS in motor neurons in rodent's lifetime. Int J Biol Sci (2010) 1.01
Analysis of mouse skin reveals proteins that are altered in a diet-induced diabetic state: a new method for detection of type 2 diabetes. Proteomics (2007) 1.01
Evolutionary emergence of microRNAs in human embryonic stem cells. PLoS One (2008) 0.98
Formulation and optimization of sustained release matrix tablet of metformin HCl 500 mg using response surface methodology. Yakugaku Zasshi (2007) 0.98
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem (2007) 0.97
Selective binding of TAR RNA by a Tat-derived beta-peptide. Org Lett (2003) 0.96
Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem (2009) 0.95
Optimization of metformin HCl 500 mg sustained release matrix tablets using Artificial Neural Network (ANN) based on Multilayer Perceptrons (MLP) model. Chem Pharm Bull (Tokyo) (2008) 0.95
Additivity in the analysis and design of HIV protease inhibitors. J Med Chem (2009) 0.95
XBP1 depletion precedes ubiquitin aggregation and Golgi fragmentation in TDP-43 transgenic rats. J Neurochem (2012) 0.94
Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. J Med Chem (2010) 0.93
Promises and challenges in developing RNAi as a research tool and therapy for neurodegenerative diseases. Neurodegener Dis (2005) 0.93
An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. J Neurochem (2005) 0.92
Gene regulation by non-coding RNAs. Crit Rev Biochem Mol Biol (2013) 0.92
Inhibition of chaperone activity is a shared property of several Cu,Zn-superoxide dismutase mutants that cause amyotrophic lateral sclerosis. J Biol Chem (2005) 0.92
RNA-based mechanisms regulating host-virus interactions. Immunol Rev (2013) 0.92
SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity. Biochem Biophys Res Commun (2007) 0.90
TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice. Int J Biol Sci (2011) 0.88
Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication. ChemMedChem (2012) 0.87